Amgen’s IMDELLTRA granted full approval by FDA for treating ES-SCLC patients with disease progression after platinum-based chemotherapy. Data from Phase 3 DeLLphi-304 study supports decision. NCCN Guidelines updated to include tarlatamab as preferred treatment option. Study shows IMDELLTRA reduces risk of death by 40% and extends median overall survival by over five months compared to standard chemotherapy for ES-SCLC patients who progressed after platinum-based chemotherapy. Visit rttnews.com for more health news. (Source: RTTNews)

Read more at Nasdaq: Amgen’s IMDELLTRA Gets Full FDA Approval For Extensive Stage Small Cell Lung Cancer